Retrospective Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Mar 6, 2022; 10(7): 2115-2126
Published online Mar 6, 2022. doi: 10.12998/wjcc.v10.i7.2115
Table 1 Patient baseline characteristics among borderline ovarian tumors and epithelial ovarian cancer before propensity score matching and after propensity score matching
VariablesBefore PSM
After PSM
BOTs (n = 192)
EOC (n = 371)
P value
BOTs (n = 192)
EOC (n = 192)
P value
Age at diagnosis (years) 41.0 ± 15.251.0 ± 11.8< 0.000141.0 ± 15.245.8 ± 12.80.0008
Body mass index (kg/m2)22.6 ± 3.223 ± 8.10.515922.6 ± 3.222.4 ± 30.5189
Menopausal status (%)< 0.00010.565
Premenopausal143 (74.5)176 (47.4)143 (74.5)138 (71.9)
Postmenopausal49 (25.5)194 (52.3)49 (25.5)54 (28.1)
Unknown0 (0)1 (0.3)0 (0)0 (0)
Parity (%)< 0.0001< 0.0001
Nulliparous6 (3.1)0 (0)6 (3.1)0 (0)
Parous133 (69.3)334 (90)133 (69.3)164 (85.4)
Unknown53 (27.6)37 (10)53 (27.6)0 (0)
Preoperative CA125>35 IU/mL (%)< 0.0001< 0.0001
Elevated107 (55.7)320 (86.3)107 (55.7)163 (84.9)
Normal76 (39.6)37 (10)76 (39.6)19 (9.9)
Unknown9 (4.7)14 (3.8)9 (4.7)10 (5.2)
Preoperative CA199>34 IU/mL (%)0.9450.827
Elevated54 (28.1)104 (28)54 (28.1)58 (30.2)
Normal110 (57.3)209 (56.3)110 (57.3)104 (54.2)
Unknown28 (14.6)58 (15.6)28 (14.6)30 (15.6)
Tumor localizations0.1530.196
LO44 (22.9)99 (26.7)44 (22.9)54 (28.1)
RO86 (44.8)165 (36.4)86 (44.8)69 (35.9)
Unknown62 (32.3)137 (36.9)62 (32.3)69 (35.9)
FIGO stage (%)< 0.0001< 0.0001
168 (87.5)151 (40.7)168 (87.5)85 (44.3)
7 (3.6)34 (9.2)7 (3.6)16 (8.3)
17 (8.9)169 (45.6)17 (8.9)80 (41.7)
0 (0)17 (4.6)0 (0)11 (5.7)
Surgical type (%)0.00050.0005
BSO7 (3.6)4 (1.1)7 (3.6)1 (0.5)
HB13 (6.8)8 (2.2)13 (6.8)4 (2.1)
HBO5 (2.6)31 (8.4)5 (2.6)17 (8.9)
HBOA8 (4.2)15 (4)8 (4.2)11 (5.7)
HBOL77 (40.1)291 (78.4)77 (40.1)146 (76)
TR34 (17.7)6 (1.6)34 (17.7)5 (2.6)
USO48 (25)13 (3.5)48 (25)7 (3.6)
CS0 (0)3 (0.8)0 (0)1 (0.5)
Postoperative adjuvant therapy (%)< 0.0001< 0.0001
Yes64 (33.3)292 (78.7)64 (33.3)156 (81.3)
No125 (65.1)78 (21)125 (65.1)36 (18.8)
Unknown3 (1.6)1 (0.3)3 (1.6)0 (0)